Drug Trial Radar · NCT06926582
A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
305
Planned (sponsor's estimate)
Start
Apr 9, 2025
Primary completion
Jul 9, 2026
Study completion Dec 9, 2026
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Apr 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.
Conditions
- Psoriasis
Interventions
HS-10374 6mg tabletsDrug
Administered orally QD for 12 weeks
HS-10374-matched placebo tabletsDrug
Administered orally QD for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients achieving sPGA 0/1 with at least 2 points improvement from baseline at Week 12Time frame: Baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.